Group B streptococcal screening, intrapartum antibiotic prophylaxis, and neonatal early-onset infection rates in an Australian local health district: 2006-2016 by Braye, K et al.
RESEARCH ARTICLE
Group B streptococcal screening, intrapartum
antibiotic prophylaxis, and neonatal early-
onset infection rates in an Australian local
health district: 2006-2016
Kathryn BrayeID
1,2☯*, Maralyn Foureur1,2,3☯, Koert de Waal4,5‡, Mark Jones6‡, Elise Putt2☯,
John Ferguson2,5,7☯
1 Faculty of Health, University of Technology, Sydney, New South Wales, Australia, 2 Hunter New England
Health, Newcastle, New South Wales, Australia, 3 School of Nursing and Midwifery, University of Newcastle,
Newcastle, New South Wales, Australia, 4 Department of Neonatology, John Hunter Hospital, Newcastle,
New South Wales, Australia, 5 School of Biomedical Sciences and Pharmacy, University of Newcastle,
Newcastle, New South Wales, Australia, 6 Hunter Medical Research Institute, Newcastle, New South Wales,
Australia, 7 New South Wales Health Pathology, Newcastle, New South Wales, Australia
☯ These authors contributed equally to this work.




Intrapartum antibiotic prophylaxis (IAP) to reduce the likelihood of neonatal early-onset
group B streptococcal infection (EOGBS) has coincided with major reductions in incidence.
While the decline has been largely ascribed to IAP following either universal screening or a
risk-based approach to identify mothers whose babies may most benefit from IAP, there is
lack of high quality evidence to support this view.
Aims
To describe management of maternal GBS colonisation in one local health district using uni-
versal screening and assess rates of EOGBS over time.
Methods
A retrospective cohort study was undertaken to describe compliance with GBS manage-
ment, to determine the incidence of EOGBS and association between rates and maternal
screening. Linking routinely collected maternity and pathology data, we explored temporal
trends using logistic regression and covariates for potential effect modifiers.
Results
Our cohort included 62,281 women who had 92,055 pregnancies resulting in 93,584 live
born babies. Screening occurred in 76% of pregnancies; 69% had a result recorded, 21.5%
of those were positive for GBS. Prophylaxis was used by 79% of this group. Eighteen babies
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developed EOGBS, estimated incidence/1000 live births in 2006 and 2016 was 0.35 (95%
CI, 0.07 to 0.63) and 0.1 (95% CI, 0 to 0.2) respectively. Seven of 10 term babies with
EOGBS were born to mothers who screened negative. Data were unable to provide evi-
dence of difference in rates of EOGBS between screened and unscreened pregnancies.
We estimated the difference in EOGBS incidence from crude and weighted models to be 0
(95% CI, -0. 2 to 0.17) and -0.01 (95% CI, -0.13 to 0.10) /1000 live births respectively.
Conclusion
No change was detected in rates of EOGBS over time and no difference in EOGBS in
babies of screened and unscreened populations. Screening and prophylaxis rates were
modest. Limitations of universal screening suggest alternatives be considered.
Introduction
Early-onset group B streptococcal infection (EOGBS) is a high impact event that, despite its
low frequency, remains a significant cause of early infant morbidity and mortality [1]. To
reduce the likelihood of EOGBS, intrapartum antibiotic prophylaxis (IAP) was introduced in
the 1980s and offered to women whose babies were thought to be most at risk. In the United
States of America (USA), widespread use of IAP coincided with a decline in reported EOGBS
rates; from 0.7/1000 live births in 1997 [2] to 0.22/ 1000 in 2016 [3]. However, since the pre-
prevention era, the proportion of women and babies exposed to IAP has more than doubled
(from 12% to 30%) in the USA and other high-income countries [4].
Antibiotics have saved millions of lives, but they are not without risk. Most recently con-
cerns have been raised about the possible link between IAP exposure and dysbiosis of the
infant’s founding microbiome, which may lead to adverse health effects in later life [5–9].
Research which highlights benefits, risks and limitations of GBS screening and IAP provision
is therefore warranted.
Background
Neonatal group B streptococcal colonisation and infection. Prior to the implementation
of screening and IAP provision, it was believed that up to 50% of babies born vaginally to
mothers with GBS colonisation would be colonised by the bacterium as part of their founding
microbiome. Most of these babies were not compromised by GBS colonisation and remained
well [10, 11]. In the absence of IAP, it is reported that 1–3% of babies colonised with GBS will
develop EOGBS [12]; however, this proportion is difficult to quantify in the era of widespread
IAP. In a global systematic review and meta-analysis, the incidence of EOGBS was 0�43/ 1000
live births (95% CI, 0�37–0�49) and global case fatality 12�1%, (6�2–18�3) [1].
Screening approaches. In 1996 the centers for disease control and prevention (CDC)
published guidelines recommending that clinicians select women whose babies may benefit
from IAP and offer prophylaxis to reduce the likelihood of EOGBS. The selection criteria were
based on certain risk factors including maternal recto-vaginal GBS colonisation, rupture of
membranes (ROM)�18 hours, intrapartum fever and prematurity [12–14]. History of bacteri-
uria in the index pregnancy and having a sibling diagnosed with EOGBS are also risk factors
[12, 13].
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In 2002, based on a large retrospective study in the USA [15], the CDC recommended uni-
versal screening for vaginal and rectal GBS colonisation of all pregnant women at 35–37
weeks’ gestation as the best method for GBS management [16]. When GBS status was
unknown, a risk-based based approach for IAP was recommended. In 2010 the CDC contin-
ued to recommend universal screening [12] although globally, countries remain divided
regarding optimal GBS management.
In Australia the evolution of GBS management strategies began in the late 1970s, based on
the observation of an unexpectedly large number of EOGBS reported in one city. As a conse-
quence of a review into local EOGBS rates in a large metropolitan Melbourne hospital, policy
recommended a universal GBS screen for pregnant women and provision of IAP to those at
risk [17]. This review influenced GBS management throughout the country. However Austra-
lia has never had a national GBS policy and Australian states and territories recommend differ-
ent approaches for selecting women for IAP. Queensland, for example, recommends a risk-
based approach [18] and NSW recommends either universal screening or a risk-based
approach [19]. The latest guidelines from the Royal Australian and New Zealand college of
Obstetricians and Gynaecologists (RANZCOG) [13] also recommend either approach. Con-
versely, New Zealand has undertaken local research [20–22] and continues to offer a risk-
based approach to manage GBS risk. A recent Australian systematic review concluded that the
odds of EOGBS in infants of any gestation were significantly lower with universal screening
compared with risk-based screening (OR 0.45, 95% CI, 0.37–0.53). However the authors noted
the quality of the studies critiqued was low [23].
Incidence of early-onset group B streptococcal infection. Reported rates of neonatal
EOGBS vary markedly, particularly in areas with limited access to laboratory diagnosis. Varia-
tion in rates may reflect changes in reporting of cases and/or natural fluctuation, a true
increase or decrease in incidence, or less than optimal implementation of prevention strate-
gies. Rates of EOGBS are often reported on a voluntary basis and therefore may not represent
all confirmed cases. Our data include live births only. Although it is probable that GBS was a
contributing factor in a proportion of stillborn babies in our district [24], it was not possible to
obtain data on these babies.
Reported live birth rates of EOGBS in the USA, and other high-income countries including
Australia, have remained stable for nearly two decades, at below 0.5/1000 live births [12, 25,
26]. Exceptions include New Zealand where researchers compared 1998–99 EOGBS rates
which were estimated at 0.5/1000 live births (95% CI, 0.38, 0.65) [22] to rates five years later
after instituting a national consensus risk-based approach. In 2009–11 EOGBS rates had
halved to 0.26/1000 live births (95% CI, 0.18–0.37) [21]. Other countries have reported an
increase in rates. The UK from 0.48/1,000 live births (95% CI, 0.43 to 0.53) in 2000–2001 to
0.57/1,000 live births in 2014/2015 (95% CI, 0.52–0.62) and [14] the Netherlands 0�11/1000
live births to 0�19/1000 live births (p<0�0001.)[16].
Local practice. In 2005, our local health district, now called Hunter New England Local
Health District (HNELHD), changed GBS management from identification of risk factors to
universal culture based screening and provision of IAP in line with the CDC guidelines of the
time [16]. A local study, reported a dramatic decline in EOGBS (84%) when universal screen-
ing was employed to select candidates for IAP. The study reported that to prevent one case of
the infection 5,704 women needed to be screened and 1,911 women with a positive GBS result
would be required to have IAP [27].
The regime for IAP was set locally at 1.2-grams of penicillin followed by 600mg four hourly
until birth [28] and, due to our very low EOGBS rates, this regime has not changed despite the
Australian therapeutic guidelines [29] and CDC [30] recommendations of 3-grams of penicil-
lin followed by 1.5–1.8 grams four hourly until birth. Over a decade has passed since this local
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study and the change from a risk-based approach to universal screening. We were interested
to assess compliance with universal GBS screening and IAP protocols and EOGBS rates in this
population.
Aims
To describe compliance with GBS management in an era of universal screening and to assess
rates of neonatal EOGBS over time in a diverse Australian local health district.
Methods
Study setting and population
A retrospective cohort study was employed using data from pregnancies that resulted in live
born babies in the Hunter New England local health district, New South Wales (NSW) Austra-
lia, over the period 2006–2016.
The study population included women whose pregnancies resulted in live born babies
birthing in all publicly funded maternity services within HNELHD and their babies. The term
“pregnancies” or “women whose pregnancies” is used in this paper as around one third of
women had more than one pregnancy during the study period. Included births occurred in
hospitals, alongside and freestanding birth centres and at home, between 1st January 2006 and
31st December 2016 Table 1.
Information concerning babies and their mothers was obtained from the maternity Obste-
triX database and the NSW Health Pathology database (Auslab). ObstetriX (now e. Maternity)
is a state wide surveillance system providing point-of-care data collection across antenatal,
intrapartum and immediate postnatal periods. Clinicians contribute information soon after
birth. The database is maintained by local health district (LHD) data custodians. The medical
records of babies affected by EOGBS and their mothers were also scrutinised. Provision of IAP
was documented in the medical record with two clinicians signing for receipt and timing of
the medication.
Table 1. Pregnancies resulting in live born babies per unit 2006–2016.
Birthing unit Pregnancies Babies
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We collected data on maternal antenatal and intrapartum risk factors, together with neona-
tal outcomes for the 18 babies with confirmed EOGBS. Maternal GBS colonisation, prematu-
rity, ROM�18 hours and maternal age were collected and used in analysis. While intrapartum
fever, history of maternal GBS bacteriuria and history of a previous child with EOGBS are risk
factors, and therefore considered in a decision to offer IAP, we were unable to obtain informa-
tion on these variables at a population level.
Microbiological cultures
Neonatal EOGBS can be defined as culture proven GBS bacteria found in a normally sterile
site; either blood, causing sepsis or cerebrospinal fluid (CSF) causing meningitis, or both [31].
Researchers use a range of time frames to define early-onset; from 48 hours to 7 days post
birth. We applied the definition used by the National Institute for Health Care and Excellence
(NICE) guidelines. This guideline defines EOS as sepsis occurring�72 hours after birth [31].
Neonatal cultures positive for GBS were accessed from the NSW health pathology database
used for most public health pathology across HNELHD. Blood and CSF culture data were also
accessed from 3 of 4 private providers who service small facilities in the north-western region
of HNELHD.
Gestation and eligibility for group B streptococcal screening
Term gestation was defined as�37 weeks gestation, preterm <37 weeks gestation. Eligibility
for GBS screening applied to all women whose pregnancies were�35 weeks gestation, which
includes a small number of women whose pregnancies were preterm. Pregnancies that reached
�35 weeks but<37 weeks gestation were classified as “eligible preterm pregnancies”. Screen-
ing should occur within five weeks of birth to maximise accuracy [26].
Definition of screened and not screened
Identification of women whose pregnancies were screened or not screened required the com-
bination of several fields within the obstetric database. Eligible pregnancies were regarded as
“screened” if they met either of two categories: “screened with a result” available intrapartum
or at ROM (n = 60,674 69%) or “Screened with no result” where screening results were not
available or pending at the time of birth or ROM. Women whose pregnancies were regarded
as “not screened” occurred if there was no entry in the ObstetriX database or a text entry that
stated either “screening declined” or “not screened”.
Definition of adequate intrapartum antibiotic prophylaxis
Intrapartum antibiotic prophylaxis was defined as adequate when the initial dose of IAP was
given at least four hours prior to birth in line with current CDC and RANZCOG guidelines
[12, 13].
Mortality and morbidity
Live status (as of December 2017) for each baby who had experienced an EOGBS event was
derived from the HNELHD patient demographics system linked to NSW death registration
data. Admission and short-term morbidity were reported as serious or not serious. Serious
morbidity was defined as the need for significant respiratory support requiring neonatal inten-
sive care; or circulatory support and/or encephalopathy or seizures. It was not possible to
assess long-term morbidity in our study.
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Ethics approval
The study was deemed by the chair of Hunter New England (HNE) human research ethics
committee (HREC) not to require formal approval by the ethics committee. The study con-
forms to the obligations of the provision of privacy and confidentiality of patient data and clin-
ical information, including NSW Health records and Information Privacy Act 2002 as
requested in our letter of approval from HNE research Ethics and Governance unit. University
of Technology Sydney, HREC, ratified this decision. No. 2014000115. Data were de-identified
for the purposes of this study. Individual consent was not required.
Statistical analysis
Descriptive statistics for women, their pregnancies, and live born babies are provided Table 1.
Early-onset GBS incidence rates were calculated as events/1000 live births per year. We
explored EOGBS in the babies of all women whose pregnancies reached�35 weeks gestation
and were therefore eligible for GBS screening. Given the low number of EOGBS events we
report both crude and inverse probability weighting to balance groups. The inverse probability
weights were estimated using a separate logistic regression model with screening status as the
outcome regressed on variables plausibly related to EOGBS and/or screening including gesta-
tion, birth weight, positive maternal GBS screening, ROM�18 hours and maternal age at each
pregnancy (categorical indicating <20 years or all others). We also used logistic regression to
model trends in EOGBS incidence over time. All models were checked for calibration and dis-
crimination and we used a conventional significance level of 0.05 throughout.
Results
Study population
Sixteen publicly funded birthing units were included Table 1 ranging from one metropolitan
facility with an alongside birth centre and an associated freestanding birth centre nearby (in
total around 4000 births per year), several regional units (700 to 1500 births per year) through
to small rural units (<250 births per year).
After exclusions, (babies who were stillborn and entries with inadequate or duplicate data)
the study population included 62,281 women who had 92,055 pregnancies over the study
period resulting in 93,584 live born babies. Ninety-eight per cent of babies (90,510) were sin-
gletons and 9.7% (9,146) of babies were preterm. Sixty-five babies had confirmed EOS. We
found 18 babies with EOGBS, 10 term and eight preterm (0.19/1000 live births) Fig 1. Half of
the term babies with EOGBS were born in the metropolitan unit and half in regional units.
One was transferred from a regional unit to a higher level of care. All preterm babies with
EOGBS were born at the metropolitan unit.
Maternal GBS screening, colonisation and antibiotic prophylaxis
Nearly all women (96%) in our study had pregnancies� 35 weeks and therefore were eligible
for GBS screening. Seventy-six per cent of those eligible were reported to have a GBS screen.
Of those, 69% had a result recorded in the database and 21.5% of those pregnancies were posi-
tive for GBS Table 2. Antibiotic prophylaxis was received by 79% of these women. Rates of pos-
itive maternal GBS colonisation in the cohort neither changed significantly from year to year
nor materially between 2006 and 2016 Fig 2. Twelve per cent of women whose pregnancies
were reported as GBS negative also received IAP Table 2. Reasons for administration of IAP to
these women were not collected. Whether adequate IAP was given (�4 hours before birth)
could not be determined at a population level but was identified in individual cases.
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Early-onset group B streptococcal infection over time
The odds ratio for the annual temporal trend of EOGBS obtained from the exponentiated
parameter estimates was 0.88 (95% CI, 0.75 to 1.03, p = 0.11). Model estimates for incidence
per /1000 live births in 2006 and 2016 were 0.35 (95% CI, 0.07 to 0.63) and 0.1 (95% CI, 0 to
0.2) respectively Fig 4. A bootstrapped estimate for the difference between the 2006 and 2016
incidence of EOGBS was -0.28 (95% CI, -0.04 to 0.74) suggesting negligible support for a
change even over the 10-year interval.
Eligible babies with early-onset group B streptococcal infection
Ten term (therefore eligible) babies had EOGBS, a crude rate of 0.12/1000 term live births. All
of these babies had mothers who were screened for GBS. These babies either had an eligible
mother with a negative antenatal GBS screen (n = 7) or a mother with a positive GBS result
that was unknown in labour and thus was unable to trigger IAP (n = 3). Six of the seven nega-
tive cultures were taken within five weeks of birth.
A further preterm baby, whose mother was eligible for GBS screening (� 35 weeks gesta-
tion) and had a positive result known in labour and was subsequently diagnosed with EOGBS.
Six of these 11 babies had additional risk factors documented (prematurity and/or maternal
GBS colonisation, ROM� 18 hours, fever), which would qualify for IAP using a risk-factor
only approach.
Two mothers in the eligible group received some IAP, however neither of these women
received a dose�4 hours before birth.
Preterm babies with early-onset group B streptococcal infection
Eight babies with EOGBS were preterm (0.87/1000 preterm live births). Gestations ranged
from 24 to 36 weeks. Two mothers in the preterm group received IAP (including the mother
Fig 1. Inclusions and exclusions. EOGBS = early-onset group B streptococcal infection.
https://doi.org/10.1371/journal.pone.0214295.g001
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IAP given for GBS pos
pregnancies (%)
IAP given for eligible not
screened pregnancies (%)
John Hunter Hospital 38,885 32,011 (82) 29,529 (76) 7,089 (24) 5,600 (79) 825 (12)
Maitland 17,051 11,494 (67) 10,954 (64) 2,407 (22) 1,918 (80) 527 (9)
Tamworth 7,873 5,178 (66) 4,764 (61) 827 (17) 695 (84) 390 (14)
Manning 6,235 4,615 (74) 3,453 (55) 632 (18) 501 (79) 156 (10)
Armidale 3,781 2,411 (64) 2,148 (57) 401 (19) 359 (90) 202 (15)
Inverell 2,257 1,918 (85) 1,584 (70) 272 (17) 227 (83) 67 (20)
Muswellbrook 2,167 1,885 (87) 1,856 (86) 353 (19) 280 (79) 35 (12)
Belmont Midwifery
Group Practice
1,996 1,479 (74) 1,417 (71) 297 (21) 24 (8) 4 (1)
Singleton 1,785 1,403 (79) 1,222 (68) 216 (18) 193 (89) 45 (12)
Moree 1,684 1,318 (78) 1,036 (62) 95 (9) 88 (93) 111 (30)
Gunnedah 1,621 1,432 (88) 996 (61) 164 (16) 148 (90) 66 (35)
Narrabri 1,223 816 (67) 583 (48) 64 (11) 44 (69) 71 (17)
Scone 876 673 (77) 646 (74) 140 (22) 127 (91) 27 (13)
Glen Innes 660 436 (66) 366 (55) 82 (22) 78 (95) 49 (22)
Gloucester 121 100 (83) 91 (75) 15 (16) 13 (87) 7 (33)
Manilla 51 33 (65) 29 (57) 4 (14) 3 (75) 0 (0)
TOTALS 88,266 67,202 (76) 60,674 (69) 13,058
(22)
10,298 (79) 2,582 (12)
Eligible pregnancy�35 weeks gestation, Pos = positive, Neg = negative, IAP = intrapartum antibiotics prophylaxis
None of our models gave evidence that the screened and unscreened cohorts had differing rates of EOGBS Fig 3. We estimated the difference in EOGBS incidence
across reported screening status from the crude and weighted models to be 0 (-0.2 to 0.17) /1000 live births and -0.01 (95% CI, -0.13 to 0.10) /1000 live births
respectively. Adjusting for a temporal trend did not materially impact the estimates.
https://doi.org/10.1371/journal.pone.0214295.t002
Fig 2. Maternal GBS colonisation.
https://doi.org/10.1371/journal.pone.0214295.g002
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who was 36 weeks gestation and therefore eligible preterm), but neither dose was
provided� four hours before birth.
Morbidity and mortality
Four of 10 term babies with EOGBS had serious short-term morbidity. All required neonatal
intensive care and significant continuous positive airways pressure therapy, one baby had seizure
activity. All four were discharged home in a well state and were recorded as living as of December
2017, as were the other six. One preterm baby born<32 weeks gestation died (0.11/1000 live born
preterm births) a combined term and preterm crude fatality rate of 0.01/1000 live births.
Discussion
This cohort study describes the management of GBS risk in our LHD in an era of universal
screening and describes analysis of the rates and trends of EOGBS in an 11-year period in a
diverse range of birth settings.
Fig 3. Screened versus unscreened pregnancies and rates of EOGBS. EOGBS = early-onset group B streptococcal infection.
https://doi.org/10.1371/journal.pone.0214295.g003
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We found no evidence to conclude a difference in rates of EOGBS between women
reported as screened or not screened for GBS. Our findings, along with others [32–34], high-
light the logistical difficulty of mounting a sustained, consistent screening program across a
large LHD. Furthermore, 12% of women who were not screened received IAP Table 2. The
reasons for this were not analysed in this study.
Incidence of EOGBS in this population was low, at 0.19/1000 live births. The low frequency
of EOGBS events limited our ability to explore time trends in incidence rates however our
model did not provide evidence of a change in incidence over time. Our data align with the
contemporary incidence rates recorded by a large, multi-centre study from the US, (0.2/1000
live births) [35].
It is possible and widely reported, that the rates of EOGBS may have remained low since
the early 2000s because of screening and IAP provision [1, 34–36]. We found 21.5% of the 69%
of pregnancies who were screened and had a result documented in the database, were positive
for GBS. A modest 79% of women, who were positive for GBS at the end of their pregnancy,
received some IAP Table 2. This finding is similar to the results found in a recent Australian
integrative review [37]. The review found that although screening and IAP appeared to be very
effective in reducing rates of EOGBS, the rate of IAP provision in the clinical setting was not
optimal suggesting there may be other reasons for very low EOGBS rates. The database in our
study did not specify the dose or frequency of IAP provision, so we could not establish if the
IAP provided was assessed as adequate at a population level. At an individual level, to explore
the experience of babies who had EOGBS, we examined individual medical records to obtain
data not entered onto the ObstetriX database. None of the babies with EOGBS had mothers
who were provided with adequate IAP.
In this era of universal screening and IAP provision there is no way of knowing what the
rates of EOGBS in high income countries would be in babies whose mothers had GBS risk fac-
tors but no exposure to IAP. When data are compared from jurisdictions that use universal
screening and IAP, versus a method based on risk factors, reported EOGBS rates are mixed,
with either no change [25] increases in some jurisdictions [26,38] and decreases in others [21].
It should be noted, however, that some clinicians use a combination of the two standard
Fig 4. Incidence of term and preterm EOGBS 2006–2016.
https://doi.org/10.1371/journal.pone.0214295.g004
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methods of selecting women most at risk of having a baby affected by this infection [39] so
comparison between countries, and even areas within countries, is problematic.
Seven out of the ten term babies with EOGBS had mothers who were screened negative for
GBS. These data concur with others reporting on EOGBS in the era of widespread IAP provision,
finding rates of infection occurring among babies born to women with pregnancies negative for
GBS were higher than previously reported [35, 40]. There are several reasons why this may be the
case. These false negative results may be due to the modest predictive values of current screening
protocols; which are influenced by intermittent maternal GBS colonisation [26]. Further, in some
jurisdictions, swabs may be incorrectly taken and /or transported, or incorrectly processed [14].
Five of the seven term women whose pregnancies screened negative for GBS had another
risk factor for infection (ROM�18 hours) warranting consideration for IAP using a risk-
based approach. Even though the most common risk factor for EOGBS in our study and others
[41, 42] was ROM�18 hours, numbers were too small (5/7 term women) to draw any conclu-
sion. IAP was not administered to the five women with ROM�18 hours and a negative GBS
result, in accord with local guideline recommendations at the time. Early-onset infection due
to GBS occurring in babies born to women whose pregnancies have screened negative for
GBS, further reflects the limitations of current methods of assessing GBS risk in our area.
As well as the protocol of screening and IAP provision that was offered to most, but not all,
women with pregnancies that had a GBS positive result, it is likely that the low rates of EOGBS
in our cohort maybe related to other factors. It is true that the crude rates of maternal GBS col-
onisation in the cohort neither changed significantly from year to year nor materially between
2006 and 2016. However, shifts in GBS serotypes and/or virulence of the bacteria may have
occurred. Furthermore, population differences in exposure to GBS, maternal immunity, and
foetal/neonatal susceptibility may also play a role in the reduction of infection rates [43]. Our
low incidence of EOGBS in term babies cannot be exclusively ascribed to the protocol of offer-
ing women universal GBS screening and IAP.
Term babies in our study, diagnosed with EOGBS, were promptly treated and all survived.
Case fatality in preterm babies with EOGBS was 0.01/1000 preterm live births.
Reduction in mortality since the 1970s, which was then as high as half of both term and pre-
term babies with EOGBS, is thought to be largely due to advances in maternity and neonatal
care [14].
Limitations
Like many before, this study underestimates the true burden of EOGBS because it focuses on
live born babies with culture-proven events, missing stillbirths and cases of clinical infection.
Due to the rarity of EOGBS small case numbers prevented a more in-depth analysis; particu-
larly of screened versus non-screened pregnancies.
We were unable to accurately record incidences of intrapartum fever and some other risk
factors; a previous baby with EOGBS or bacteriuria in the index pregnancy and we were unable
to access information for babies who were term and otherwise well but may have received anti-
biotics because of deemed inadequate chemoprophylaxis.
Our study uses a retrospective ascertainment of screening results, which may suffer from
reporting bias. The high rate of undocumented GBS results in the database is a limitation and
may be due, in part, to substandard data entry.
Strengths
This retrospective study covering 11 years includes regional, rural and some remote birthing
populations using a range of birthing options; from a metropolitan unit, to smaller regional
Group B streptococcal management and neonatal early-onset infection: 2006-2016
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units, birth centres and planned homebirth. Our study is generalisable to other jurisdictions
with similar demographics and can be replicated in areas where researchers are able to collect
pathology data and link these with a maternity and neonatal database such as ObstetriX or e.
Maternity.
Future direction
Three decades ago, IAP was introduced as a safe but interim solution to manage GBS risk [35].
Mortality rates since the 1970s have dropped markedly and EOGBS is now a rare and treatable
infection, even in babies who are not exposed to IAP as this study and others report [35]. Since
the introduction of universal screening and IAP, the number of women and babies exposed to
prophylactic antibiotics in labour for GBS risk has more than doubled (12% to 30%) in some
jurisdictions. Most term babies exposed to IAP have negligible risk of succumbing to the infec-
tion and are therefore, arguably, exposed to IAP unnecessarily. Intrapartum antibiotic provi-
sion is not without its own set of risks. There is emerging speculative data associating
intrapartum antibiotics with adverse health issues later in life [5–9]. Interventions of any kind
are likely to have wider effects than acknowledged by evaluators. For ethical and methodologi-
cal reasons, it is imperative that any harmful effects of interventions as well as their short-term
benefits, are considered, analysed and, if relevant, alleviated. Furthermore, if universal screen-
ing continues to be recommended and used widely, high quality research to assess the relative
benefits and risks of a universal screening protocol versus a risk-based approach is warranted.
This will provide clinicians, women, and their families’ access to high-quality evidence to
enable them to discuss and make decisions about the risks they are prepared to embrace.
The potential for a maternal GBS vaccination to reduce the risk of EOGBS in term babies is
supported by studies, which demonstrate that higher maternal serotype-specific antibody con-
centrations are associated with a lower risk of EOGBS. However, performing field trials on
protein-conjugated GBS vaccines during pregnancy is not without its challenges, with large
efficacy trials versus limited immunogenic studies being considered once a correlate of protec-
tion is universally identified and accepted [44].
Apart from vaccination, there may be other methods of reducing missed opportunities to
provide IAP to those who would most benefit while reducing the number of mothers and
babies unnecessarily exposed to IAP. Accurate and rapid methods of intrapartum GBS testing,
aimed at a specific cohort of women who experience ROM without timely onset of labour,
may assist in the identification of GBS status and assist women and clinicians in subsequent
GBS risk management. To ensure optimum equity in maternity care, such a test should ideally
be available to women accessing a variety of birth settings. In our LHD this proposal would
require a point-of-care molecular test. Logistical and expense considerations may be challeng-
ing due to the wide variety of birth settings in our region. Point-of-care testing, however, has
been offered for some time at a large metropolitan hospital in an adjoining LHD and may
reduce the number of women and babies at term gestation unnecessarily exposed to intrapar-
tum antibiotics.
Following presentation of this study, decision makers in our LHD have resolved not to
increase the dose of prophylactic antibiotics for maternal GBS colonisation due to our very
low and stable term EOGBS rates. This HNELHD will therefore not be in line with the current
Australian therapeutic guidelines and the CDC recommendations for prophylaxis, which we
believe, warrant review.
Based on the results of this study we, along with others [45], strongly recommend that pri-
mary attention to risk factors for EOGBS infection and timely prophylaxis or antibiotic treat-
ment as indicated would be a more effective strategy for reduction of EOGBS in both preterm
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and term groups rather than the universal screening approach which failed to identify all
infants at risk.
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